What is Vonoprazan API?

Vonoprazan fumarate is a small-molecule P-CAB that suppresses gastric acid secretion through a mechanism distinct from conventional PPIs. Where PPIs require activation in an acidic environment and covalently bind to proton pumps, Vonoprazan works by competitively and reversibly blocking the potassium-binding site of the H+/K+-ATPase enzyme the gastric proton pump responsible for acid secretion.

This mechanism gives Vonoprazan several clinically relevant advantages:

• Faster onset of action acid suppression begins within hours rather than days
• CYP2C19 independence unlike PPIs, Vonoprazan’s efficacy is not affected by CYP2C19 genetic polymorphism, which varies significantly across Asian populations
• Sustained acid suppression remains effective at both daytime and nocturnal acid secretion
• Stability at low pH does not require enteric coating or acid-protected formulation

As a bulk API, Vonoprazan is manufactured as a fumarate salt with a molecular formula of C₁₇H₁₆FN₃O₂S and a molecular weight of 345.39 g/mol. Bio-Synth supplies Vonoprazan API at ≥99% purity, with total impurities not exceeding 1.0%, from its WHO-GMP certified facility in Hyderabad.

Clinical Uses of Vonoprazan in Acid Disorders

1. Gastroesophageal Reflux Disease (GERD)

GERD is the most prevalent indication for Vonoprazan. The condition results from chronic reflux of gastric acid into the oesophagus, causing symptoms ranging from heartburn and regurgitation to erosive damage of the oesophageal lining.

Vonoprazan’s ability to maintain consistent intragastric pH above 4 the threshold associated with mucosal healing makes it particularly effective for:

• Non-erosive reflux disease (NERD)
• Erosive oesophagitis (EE), including moderate to severe grades
• Maintenance therapy to prevent recurrence after healing

Clinical data show Vonoprazan achieves significantly higher healing rates in erosive oesophagitis compared to first-generation PPIs, particularly in patients with severe disease or those who previously experienced inadequate PPI response.

2. H. pylori Eradication

Vonoprazan has demonstrated superior performance in H. pylori eradication regimens an area where PPI-based triple therapy has faced declining success rates due to rising antibiotic resistance.

When used as part of triple therapy combining Vonoprazan with clarithromycin and amoxicillin, eradication rates consistently exceed those of PPI-based equivalents. This positions Vonoprazan-based regimens as a preferred protocol in treatment guidelines across several Asian markets, with growing global adoption.

For formulation companies developing fixed-dose combination products or standalone H. pylori treatment packs, sourcing a reliable Vonoprazan API with documented purity and stability profiles is essential to regulatory submission readiness.

3. Peptic Ulcer Disease

Vonoprazan is indicated in the treatment and prevention of gastric and duodenal ulcers, including NSAID-associated ulcers. Its rapid and sustained acid suppression accelerates mucosal healing and reduces the risk of complications such as bleeding in high-risk patient populations.

4. Zollinger-Ellison Syndrome and Hypersecretory Conditions

In conditions characterised by pathological hypersecretion of gastric acid such as Zollinger-Ellison syndrome the potency and reliability of Vonoprazan’s acid suppression make it a clinically appropriate option where conventional PPIs may be insufficient.

Why Vonoprazan Matters to API Buyers

The clinical differentiation of Vonoprazan from PPIs has a direct commercial consequence: prescribers are actively switching patients, and Indian formulation manufacturers are building Vonoprazan-based product portfolios for both domestic and export markets.

Procurement teams sourcing Vonoprazan API face risks that go beyond price. Dependence on third-party intermediates exposes buyers to pricing shocks, inconsistent impurity profiles, and delayed production timelines. Choosing a manufacturer with vertically integrated intermediate production eliminates that exposure at the source.

Bio-Synth manufactures both key Vonoprazan intermediates Pyridine-3-sulfonyl chloride (≥99.0% purity) and 5-(2-fluorophenyl)-1H-pyrrole-3-carbaldehyde (≥95.0% purity) in-house at its Hyderabad facility, with a monthly production capacity of 750 kg of finished Vonoprazan API.

For companies also building gastrointestinal portfolios around acid and motility disorders, complementary molecules such as Metoclopramide API for gastroparesis and nausea management are available from the same certified source simplifying vendor consolidation and qualification workflows.

Vonoprazan API Specifications at a Glance

Regulatory Readiness and Documentation

For formulation manufacturers filing dossiers in regulated or semi-regulated markets, the quality of API documentation is as critical as the molecule itself. Bio-Synth provides full regulatory support including Certificate of Analysis (CoA), Drug Master File (DMF) readiness, batch-specific stability data, and analytical method documentation reducing the regulatory burden on buyers and shortening time-to-market.

This commitment to documentation integrity is a direct extension of Bio-Synth’s over eight decades of API manufacturing experience and its compliance infrastructure across cGMP, GLP, and GDP standards.

Procurement teams evaluating the full range of available gastrointestinal and specialty APIs can review Bio-Synth’s complete APIs list for visibility across therapeutic categories.

Conclusion

Vonoprazan API represents a genuine clinical and commercial advancement over conventional acid suppressants. Its mechanism of action, superior efficacy profile in GERD and H. pylori eradication, and growing global regulatory acceptance make it one of the most strategically important molecules in the gastrointestinal category today.

For Indian formulation manufacturers, establishing a reliable supply relationship with a WHO-GMP certified Vonoprazan API manufacturer is not optional; it is foundational to product quality, regulatory approval, and supply continuity. To review full product specifications, discuss bulk supply terms, or request a quotation, contact Bio-Synth directly.

FAQ

1. What is Vonoprazan API, and how does its mechanism differ from conventional PPIs?

Vonoprazan fumarate is a Potassium-Competitive Acid Blocker (P-CAB) that reversibly blocks the potassium-binding site of the H+/K+-ATPase enzyme. Unlike PPIs, it does not require acidic activation or covalent binding, enabling faster onset (hours, not days), CYP2C19 independence, sustained daytime and nocturnal suppression, and stability at low pH without enteric coating.

2. What are the primary clinical indications for formulations containing Vonoprazan API?

Key indications include:

• GERD: Non-erosive reflux disease (NERD), erosive esophagitis (all grades), and maintenance therapy
• H. pylori eradication: Triple therapy with amoxicillin and clarithromycin, showing superior eradication rates vs. PPI-based regimens
• Peptic ulcer disease: Gastric, duodenal, and NSAID-associated ulcers
• Hypersecretory conditions: Zollinger-Ellison syndrome and other pathological acid hypersecretion states

3. What are the critical API specifications and quality parameters procurement teams should verify?

Standard specifications for Vonoprazan fumarate API include:

• Molecular Formula: C₁₇H₁₆FN₃O₂S | MW: 345.39 g/mol
• Purity: ≥99%
• Total Impurities: ≤1.0%
• Unspecified Impurities: ≤0.5%
• Certifications: WHO-GMP, ISO 9001:2015
• Capacity: 750 kg/month (verify against your forecasted offtake)

4. Why does vertical integration of intermediates matter when selecting a Vonoprazan API supplier?

Dependence on third-party intermediates exposes buyers to pricing volatility, inconsistent impurity profiles, and supply delays. A vertically integrated manufacturer producing key intermediates-such as Pyridine-3-sulfonyl chloride (≥99.0%) and 5-(2-fluorophenyl)-1H-pyrrole-3-carbaldehyde (≥95.0%) in-house eliminates intermediate supply risk and ensures batch-to-batch consistency.

5. What regulatory documentation should be available to support formulation dossier submissions?

For regulated and semi-regulated market filings, the API supplier should provide:

• Certificate of Analysis (CoA) per batch
• Drug Master File (DMF) readiness
• Batch-specific stability data

Analytical method documentation

• This documentation package reduces regulatory burden and accelerates time-to-market for formulation partners.

6. Is Vonoprazan API suitable for fixed-dose combination (FDC) development, particularly for H. pylori kits?

Yes. Vonoprazan’s stability at low pH and rapid acid suppression make it ideal for FDC formulations, including co-packaged or single-tablet H. pylori regimens. When sourcing API for FDC development, confirm that the supplier’s impurity profile, particle size distribution, and excipient compatibility data support direct compression or granulation processes used in combination products.